Liver international : official journal of the International Association for the Study of the Liver · 2026
GDF-15 Levels in Cirrhosis Are Linked to Hepatic Fibrogenesis, Bacterial Translocation, and Worse Clinical Outcomes.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hofer Benedikt Silvester, Perkmann Thomas, Brusilovskaya Ksenia, Balcar Lorenz, Hintersteininger Marlene, Kramer Georg, Simbrunner Benedikt, Caparros Esther, Francés Rubén, Eichelberger Beate, Lee Silvia, Zinober Kerstin, Bödendorfer Benjamin, Radovanovic-Petrova Borka, Thöne Paul, Sebesta Christian, Jachs Mathias, Hartl Lukas, Schwabl Philipp, Mandorfer Mattias, Panzer Simon, Reiberger Thomas, Gremmel Thomas
Аннотация
BACKGROUND &AIMS: Growth differentiation factor-15 (GDF-15), a cell stress-induced cytokine, is implicated in liver disease pathophysiology. We investigated GDF-15 in cirrhosis, focusing on its association with disease-driving pathomechanisms, platelet function, hepatic decompensation, and mortality.
METHODS: We included patients with cirrhosis undergoing hepatic venous pressure gradient (HVPG) measurement at the Vienna General Hospital. Platelet surface P-selectin and glycoprotein IIb/IIIa (GPIIb/IIIa) expression after agonist stimulation were assessed by flow cytometry as platelet activation markers. GDF-15 serum levels were quantified by electrochemiluminescence immunoassay.
RESULTS: Among 106 patients (median age 55.1 years; 70.8% male), median GDF-15 was 2880 (1850-4770) pg/mL. GDF-15 correlated with hepatic dysfunction (MELD Spearman's ρ: 0.50; albumin ρ: -0.57), HVPG (ρ: 0.47), systemic inflammation (C-reactive protein ρ: 0.45; interleukin 6 [IL-6] ρ: 0.55; procalcitonin ρ: 0.58), liver stiffness (ρ: 0.67) and enhanced liver fibrosis test (ρ: 0.64) (all p < 0.001). GDF-15 was higher in patients with detectable bacterial DNA in blood (3520 vs. 2250 pg/mL; p < 0.001) and correlated with lipopolysaccharide (ρ: 0.34; p = 0.010) and lipoteichoic acid (ρ: 0.37; p = 0.004). Platelet activation was not linked to GDF-15 after adjusting for liver disease severity, yet patients with undetectable GPIIb/IIIa activation after stimulation showed significantly higher GDF-15. Over a median follow-up of 51.5 (26.0-58.2) months, 38 patients decompensated and 21 died (61.9% liver-related). GDF-15 (aHR per 100 pg/mL: 1.015; 95% CI: 1.004-1.026; p = 0.007) predicted decompensation risk independently of HVPG, MELD, albumin and IL-6. Similarly, GDF-15 was associated with higher risk of all-cause (HR: 1.019; 95% CI: 1.009-1.029; p < 0.001) and liver-related mortality (HR: 1.019; 95% CI: 1.007-1.032; p = 0.002).
CONCLUSIONS: GDF-15 is a promising biomarker in cirrhosis that reflects disease-driving pathomechanisms and independently predicts decompensation and mortality.
METHODS: We included patients with cirrhosis undergoing hepatic venous pressure gradient (HVPG) measurement at the Vienna General Hospital. Platelet surface P-selectin and glycoprotein IIb/IIIa (GPIIb/IIIa) expression after agonist stimulation were assessed by flow cytometry as platelet activation markers. GDF-15 serum levels were quantified by electrochemiluminescence immunoassay.
RESULTS: Among 106 patients (median age 55.1 years; 70.8% male), median GDF-15 was 2880 (1850-4770) pg/mL. GDF-15 correlated with hepatic dysfunction (MELD Spearman's ρ: 0.50; albumin ρ: -0.57), HVPG (ρ: 0.47), systemic inflammation (C-reactive protein ρ: 0.45; interleukin 6 [IL-6] ρ: 0.55; procalcitonin ρ: 0.58), liver stiffness (ρ: 0.67) and enhanced liver fibrosis test (ρ: 0.64) (all p < 0.001). GDF-15 was higher in patients with detectable bacterial DNA in blood (3520 vs. 2250 pg/mL; p < 0.001) and correlated with lipopolysaccharide (ρ: 0.34; p = 0.010) and lipoteichoic acid (ρ: 0.37; p = 0.004). Platelet activation was not linked to GDF-15 after adjusting for liver disease severity, yet patients with undetectable GPIIb/IIIa activation after stimulation showed significantly higher GDF-15. Over a median follow-up of 51.5 (26.0-58.2) months, 38 patients decompensated and 21 died (61.9% liver-related). GDF-15 (aHR per 100 pg/mL: 1.015; 95% CI: 1.004-1.026; p = 0.007) predicted decompensation risk independently of HVPG, MELD, albumin and IL-6. Similarly, GDF-15 was associated with higher risk of all-cause (HR: 1.019; 95% CI: 1.009-1.029; p < 0.001) and liver-related mortality (HR: 1.019; 95% CI: 1.007-1.032; p = 0.002).
CONCLUSIONS: GDF-15 is a promising biomarker in cirrhosis that reflects disease-driving pathomechanisms and independently predicts decompensation and mortality.